Ultomiris And Successor Key To AstraZeneca’s Rare Disease Ambitions
Room For Growth In Rare Diseases
Having completed its $39bn takeover of Alexion, AstraZeneca must now demonstrate its ability to maximize revenues and performance from the US rare disease specialist.
You may also be interested in...
As its acquisition by AstraZeneca moves toward closure, Alexion plans to file the Soliris follow-on for generalized myasthenia gravis in the US, EU and Japan. But potential competition awaits in the C5 inhibitor and FcRn antagonist classes.
While the sector is gripped by fears that overly zealous anti-competition regulators pose a threat to future M&A biopharma deals, AstraZeneca's acquisition of Alexion has sauntered through the US FTC's review. Its CFO Marc Dunoyer tells Scrip why the company is not surprised.
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.